Hana Securities raises Hanmi Pharmaceutical target price on potential for further Eli Lilly tech transfer

Hana Securities has upgraded its target price for Hanmi Pharmaceutical, signaling strong confidence in the company's future prospects following a significant technology transfer deal with Eli Lilly. The brokerage firm raised its target price by 10.9% to 710,000 won, while maintaining a 'buy' investment opinion.

The positive outlook is largely driven by the expectation of additional technology transfer opportunities in the latter half of this year. Hanmi Pharmaceutical recently announced a substantial contract with Eli Lilly for a treatment candidate targeting a rare disease. This deal is seen as a validation of Hanmi's research and development capabilities and a precursor to further collaborations.

With the stock currently trading at 494,000 won, the revised target price suggests significant upside potential for investors. The brokerage's assessment highlights Hanmi Pharmaceutical's ongoing innovation and its strategic positioning within the global pharmaceutical market, particularly in the development of novel therapeutics for unmet medical needs.